The TRICs up Lung Cancer's Sleeve
With Unique MOA, HER4 Joins EGFR Family Cancer Targets
By Anette Breindl
Science Editor
Science Editor
Wednesday, February 6, 2013
Studying cancer cells that survive chemotherapy treatment, scientists from Roche AG subsidiary Genentech Inc. have implicated a member of the human epidermal growth factor receptor, or HER, family in such treatment resistance.In their experiments, senior author Erica Jackson and her team looked at mouse models of non-small-cell lung cancer.
To continue reading subscribe now to Science News
Learn More about Science News
Already a subscriber? Sign In or Buy now to activate your subscription
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.